Home > News > APP Announces FDA Acceptance of New Drug
May 10th, 2004
APP Announces FDA Acceptance of New Drug
American Pharmaceutical Partners, Inc. and American BioScience, Inc.today announced that the New Drug Application for ABRAXANETM has been accepted for filing with standard review by the U.S. Food and Drug Administration, indicating the FDA has determined that the application is sufficiently complete to permit a substantive review. The final portion of the NDA was submitted on March 8, 2004 under FDA's Fast Track designation, as a treatment for metastatic breast cancer.
New non-invasive method can detect Alzheimer's disease early: MRI probe technology shows brain toxins in living animals for first time December 22nd, 2014
Enzyme Biosensor Used for Rapid Measurement of Drug December 22nd, 2014
Creation of 'Rocker' protein opens way for new smart molecules in medicine, other fields December 18th, 2014
Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014